0001562180-24-000784.txt : 20240129 0001562180-24-000784.hdr.sgml : 20240129 20240129175157 ACCESSION NUMBER: 0001562180-24-000784 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240125 FILED AS OF DATE: 20240129 DATE AS OF CHANGE: 20240129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Paggiarino Dario A. CENTRAL INDEX KEY: 0001574261 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 24575176 MAIL ADDRESS: STREET 1: 4025 SORRENTO VALLEY BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-01-25 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001574261 Paggiarino Dario A. C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 false true false false Chief Medical Officer true Common Stock 2024-01-25 4 M false 300.00 13.13 A 36805.00 D Common Stock 2024-01-25 4 M false 300.00 12.90 A 37105.00 D Common Stock 2024-01-25 4 S false 300.00 25.00 D 36805.00 D Common Stock 2024-01-25 4 S false 300.00 25.00 D 36505.00 D Stock Option (Right to Buy) 13.13 2024-01-25 4 M false 300.00 0.00 D 2031-02-09 Common Stock 300.00 51304.00 D Stock Option (Right to Buy) 12.90 2024-01-25 4 M false 300.00 0.00 D 2030-02-28 Common Stock 300.00 16635.00 D The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years. The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020 /s/ Ron Honig, Attorney-in-Fact 2024-01-29